News - Velcade, pomalidomide


Current filters:


Popular Filters

UK NICE backs Janssen’s Velcade for multiple myeloma

UK NICE backs Janssen’s Velcade for multiple myeloma


In new draft guidance published today, UK drugs watchdog the National Institute for Health and Care Excellence…

JanssenJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

NICE seeks more data on J&J’s Velcade for multiple myeloma

NICE seeks more data on J&J’s Velcade for multiple myeloma


In draft guidance published today, the UK’s drugs watchdog the National Institute of Health and Care…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalPricingRegulationVelcade

Celgene's pomalidomide meets primary endpoint in multiple myeloma


US biotech major Celgene (Nasdaq: CELG) announced that positive updated results from MM-003, a Phase…


Pomalidomide Celgene OKed in Europe


The European Commission has granted approval for US biotech firm Celgene's (Nasdaq: CELG) Pomalidomide…

BiotechnologyCelgeneEuropeImnovidOncologypomalidomidePomalidomide CelgeneRegulation

EU backs wider use of Velcade


The European Commission has approved the use of Johnson & Johnson (NYSE: JNJ) European subsidiary Janssen-Cilag's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

Strong results from meta-analysis of Takeda's Velcade in multiple myeloma


Millennium, the USA-based oncology unit of Japan's largest drugmaker Takeda Pharmaceutical (TSE:4502),…

Millennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

FDA approves Celgene's Pomalyst for advanced multiple myeloma


The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Pomalyst…

BiotechnologyCelgeneNorth AmericaOncologypomalidomidePomalystRegulation

New molecule to target pancreatic cancer treatment found by Mayo Clinic researchers


A new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more…

bortezomibJohnson & JohnsonOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Celgene's pomalidomide meets MM-003 study endpoints


US biotech firm Celgene's (Nasdaq: CELG) European subsidiary yesterday revealed that its phase III, multi-center,…


VentiRx collaborates with Celgene on cancer drug candidate; pomalidomide update


VentiRx Pharmaceuticals, a privately held US biopharmaceutical company dedicated to the development of…

BiotechnologyCelgeneLicensingNorth AmericaOncologyPharmaceuticalpomalidomideRegulationVentiRx PharmaceuticalsVTX-2337

Regulatory briefs: Celgene's pomalidomide; Lundbeck's vortioxetine


US biotech firm Celgene (Nasdaq: CELG) says that the US Food and Drug Administration's Oncologic Drugs…

Asia-PacificBiotechnologyCelgeneLundbeckNeurologicalNorth AmericaOncologyPharmaceuticalpomalidomideRegulationvortioxetine

First-line multiple myeloma patient share in Europe is variable by country


Despite the considerable heterogeneity across different European countries, surveyed hematologist-oncologists…

AlkeranBiotechnologyCelgeneGlaxoSmithKlineHealthcareJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalThalomidVelcade

Johnson & Johnson pulls EU submission for Velcade use in NHL


The European Medicines Agency has been formally notified by US health care giant Johnson & Johnson's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

Celgene slumps as it pulls new EU indication filing for Revlimid


Celgene International, the European subsidiary of USA-based Celgene Corp (Nasdaq: CELG), has provided…


5.6% annual growth forecast for multiple myeloma drug market to 2020


Driven by further penetration of Celgene’s Revlimid (lenalidomide) into the first-line setting and…

CelgeneGlobalJanssen-CilagMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

Takeda’s Millennium files two sNDAs for Velcade with US FDA


Japan’s largest drugmaker, Takeda Pharmaceutical (TSE: 4502), together with its US oncology subsidiary…

BiotechnologyMillennium PharmaceuticalsNorth AmericaOncologyPharmaceuticalRegulationTakeda PharmaceuticalsVelcade

Back to top